首页|晚期非小细胞肺癌免疫治疗:研究进展和展望

晚期非小细胞肺癌免疫治疗:研究进展和展望

扫码查看
免疫治疗已经改变了晚期非小细胞肺癌(NSCLC)的治疗格局,在一线及后线治疗中均显现出巨大潜能.同时,随着免疫治疗的广泛应用,仍有许多问题需要进一步探讨,如疗效预测生物标志物的探索、免疫治疗模式的优化、免疫相关不良反应和特殊人群的管理等.本综述梳理了晚期NSCLC免疫治疗的研究进展,并探讨了面临的挑战和未来发展方向.
Immunotherapy for Advanced Non-small Cell Lung Cancer:Research Progress and Perspectives
Immunotherapy has changed the treatment landscape of advanced non-small cell lung cancer(NSCLC),showing great potential in the treatment of untreated and relapsed or refractory(R/R)patients.However,numerous issues that need further exploration remain with the wide application of immunotherapy.They include the exploration of biomarkers for efficacy prediction,the optimization of immunotherapy modalities,immune-related adverse effects,and the management of special populations.This review summarizes the progress of the research on immunotherapy for advanced NSCLC and discusses its challenges and future directions.

Non-small cell lung cancerImmunotherapyImmune checkpoint inhibitors

王婧怡、钟雨玲、邬麟

展开 >

410013 长沙,湖南省肿瘤医院/中南大学湘雅医学院附属肿瘤医院胸内二科

421001 衡阳,南华大学衡阳医学院,湖南省肿瘤医院研究生协作培养基地

非小细胞肺癌 免疫治疗 免疫检查点抑制剂

湖南省科技创新项目湖南省科技创新项目湖南省肿瘤医院科研攀登计划北京市希思科临床肿瘤学研究基金会项目

2023SK40242021SK511212X2020005-5Y-2019Genecast-024

2024

肿瘤防治研究
湖北省卫生厅,中国抗癌协会,湖北省肿瘤医院

肿瘤防治研究

CSTPCD
影响因子:0.737
ISSN:1000-8578
年,卷(期):2024.51(6)